(120 days)
Not Found
Not Found
No
The summary describes a DNA detection kit and modifications to its labeling based on clinical study results. There is no mention of AI or ML technology.
No
The device is a diagnostic kit used for the detection of Neisseria gonorrhoeae, not for treating a condition.
Yes
The device is indicated for the "presumptive detection of Neisseria gonorrhoeae based on the detection of gonococcal DNA," which directly points to its use in diagnosing an infection.
No
The device description and intended use clearly indicate a "Gonococcal Detection Kit" which is a laboratory test kit designed to detect DNA. This involves physical reagents and laboratory procedures, not solely software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states the device is for the "presumptive detection of Neisseria gonorrhoeae based on the detection of gonococcal DNA in female endocervical and male urethral specimens." This describes a test performed in vitro (outside the body) on biological specimens to provide diagnostic information.
- Device Description: While it mentions a modification of a predicate device, the description of detecting gonococcal DNA from specimens aligns with the nature of an IVD.
- Performance Studies: The performance studies describe testing on biological specimens (endocervical specimens) and report metrics like sensitivity, specificity, PPV, and NPV, which are standard performance indicators for diagnostic tests.
The core function of the device is to analyze biological samples in vitro to aid in the diagnosis of a condition (gonorrhea), which is the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The GONOSTAT® Gonococcal Detection Kit is indicated for the presumptive detection of Neisseria gonorrhoeae based on the detection of gonococcal DNA in female endocervical and male urethral specimens. Because of some crossreactivity with DNA from N. meningitidis and some other members of the genus Neisseria, the test cannot be used with rectal or throat specimens.
Product codes
LSL
Device Description
The device is a modification of the predicate device which is also marketed by Sierra Diagnostics, Inc. The device labeling was changed to reflect the results of additional clinical studies that support claims for the use of the device in low prevalence female populations.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
female endocervical and male urethral specimens
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
An additional clinical study was performed using endocervical specimens at five study sites. The results of this study support the following changes and additions to the product labeling:
A new table of female endocervical specimen results obtained from the new study has been added. A summary of the table contents is provided below (N=3318):
Sensitivity: 98.3%
Specificity: 99.3%
Predictive value positive: 94.4%
Predictive value negative: 99.8%
Deletion of statements concerning lack of data in low prevalence populations.
An analysis of prevalence by sample type and clinical site has been added.
A chart of hypothetical predictive values at different prevalence rates has been added.
Key Metrics
Sensitivity: 98.3%
Specificity: 99.3%
Predictive value positive: 94.4%
Predictive value negative: 99.8%
Predicate Device(s)
GONOSTAT® Gonococcal Detection Kit
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.3390
Neisseria spp. direct serological test reagents.(a)
Identification. Neisseria spp. direct serological test reagents are devices that consist of antigens and antisera used in serological tests to identifyNeisseria spp. from cultured isolates. Additionally, some of these reagents consist ofNeisseria spp. antisera conjugated with a fluorescent dye (immunofluorescent reagents) which may be used to detect the presence ofNeisseria spp. directly from clinical specimens. The identification aids in the diagnosis of disease caused by bacteria belonging to the genusNeisseria, such as epidemic cerebrospinal meningitis, meningococcal disease, and gonorrhea, and also provides epidemiological information on diseases caused by these microorganisms. The device does not include products for the detection of gonorrhea in humans by indirect methods, such as detection of antibodies or of oxidase produced by gonococcal organisms.(b)
Classification. Class II (performance standards).
0
AUG 11 1999
510(k) Summary Sierra Diagnostics, Inc. GONOSTAT® Gonococcal Detection Kit
General Information on Submitter: I.
| Name: | Sierra Diagnostics, Inc. |
|---|---|
| Address: | Suite C |
| 21109 Longeway Road | |
| Sonora, CA 95370 | |
| Telephone: | (209) 539-0886 |
| Fax: | (209) 539-0853 |
| Name of Contact Person: | Tony K. Baker |
| Date Summary Prepared: | April 13, 1999 |
General Information on Device II.
GONOSTAT® Gonococcal Detection Kit Name:
DNA Reagents, Neisseria Classification Name:
GONOSTAT® Gonococcal Detection Kit III. Predicate Device:
IV. Description of the Device:
The device is a modification of the predicate device which is also marketed by Sierra Diagnostics, Inc. The device labeling was changed to reflect the results of additional clinical studies that support claims for the use of the device in low prevalence female populations.
V. Intended Use:
Presumptive detection of Neisseria gonorrhoeae based on the detection of gonococcal DNA in female endocervical and male urethral specimens. Because of some crossreactivity with DNA from N. meningitidis and some other members of the genus Neisseria, the test cannot be used with rectal or throat specimens.
Technological Characteristics of Device Compared to Predicate VI. Device:
The technological characteristics of the two devices are identical
1
Summary of Clinical Data VII.
An additional clinical study was performed using endocervical specimens at five study sites. The results of this study support the following changes and additions to the product labeling:
- A new table of female endocervical specimen results obtained from the a) new study has been added. A summary of the table contents is provided below (N=3318):
| Sensitivity: | 98.3% |
|---|---|
| Specificity: | 99.3% |
| Predictive value positive: | 94.4% |
| Predictive value negative: | 99.8% |
- c) Deletion of statements concerning lack of data in low prevalence populations.
- d) An analysis of prevalence by sample type and clinical site has been added.
- e) A chart of hypothetical predictive values at different prevalence rates has been added.
2
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circle with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol that resembles an eagle or bird with three stylized wing segments.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
AUG 11 1999
Sierra Diagnostics Mr. Donald R. Stone c/o McKenna & Cuneo, L.L.P. 1900 K Street, N.W. Washington, D.C. 20006
K991268 Re:
Trade Name: GONOSTAT® Gonococcal Detection Kit Regulatory Class: II Product Code: LSL Dated: June 28, 1999 Received: June 29, 1999
Dear Mr. Stone:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition. FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
3
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"
Sincerely yours.
Steven Autman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Indications for Use Statement
510(k) Number: K991268
Device Name:
GONOSTAT® Gonococcal Detection Kit
Indications For Use:
The GONOSTAT® Gonococcal Detection Kit is indicated for the presumptive detection of Neisseria gonorrhoeae based on the detection of gonococcal DNA in female endocervical and male urethral specimens. Because of some cross-reactivity with DNA from N. meningitidis and some other members of the genus Neisseria, the test cannot be used with rectal or throat specimens.
Woody Dubois
510(k) Numbe
(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)
OR
Prescription Use (Per 21 C.F.R. § 801.109) Over-The-Counter Use